Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer

Table 1

Partial list of ongoing clinical trials for PARP inhibitors on TNBC.

Drug/company	Trial ID	Trial	Phase
Olaparib (AZD2281)/AstraZeneca	NCT01116648	Cediranib and olaparib	II
	NCT00647062	AZD2281 and carboplatin	I
	NCT00516724	In combination with carboplatin and/or paclitaxel	I
	NCT00707707	In combination with paclitaxel	I
	NCT00679783	In known BRCA/TNBC	II
Iniparib (BSI-201)/Sanofi-Aventis	NCT01173497	Iniparib + irinotecan	II
	NCT00813956	Neoadjuvant with gemcitabine and carboplatin	II
	NCT01045304	Metastatic with gemcitabine and carboplatin	II
	NCT01204125	Neoadjuvant with paclitaxel	II
	NCT01130259	In combination with gemcitabine and carboplatin	III
Veliparib (ABT-888)/Abbott	NCT01009788	With temozolomide	II
	NCT01104259	With cisplatin and vinorelbine ditartrate	I
	NCT01306032	With cyclophosphamide	II
	NCT01042379	I-SPY2 trial	II
	NCT01251874	With carboplatin	I

Data obtained from http://www.clinicaltrials.gov, June 15, 2011.